Expert Interview
What Can We Expect from Celgene's Phase 3 REMARC Trial Data for Non-Hodgkin Lymphoma?
Ticker(s): CELGAn oncologist with significant experience treating different types of lymphoma and a familiarity with the REMARC trial.
What is your background in treating lymphoma?
Added By: kcmckeeWhat are your thoughts on the REMARC trial data presented to date?
Added By: kcmckeeWhat factors do you think will potentially help or hurt revlimid make it to market for NHL?
Added By: kcmckeeWhat attributes would make this application of revlimid superior (if at all) to existing drugs like rituximab or other recently approved options e.g. obinutuzumab, idelalisib and ibrutinib?
Added By: kcmckeeWhere do you see revlimid fitting into the NHL market?
Added By: kcmckeeWhat do you currently prescribe for NHL and could you see yourself switching to revlimid or some other drug in the near future? What developments are you most excited for in the treatment of NHL?
Added By: kcmckeeAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
- Celgene and LYSARC Provide Update on the Phase III ‘REMARC' Study of REVLIMID Maintenance Treatment in Patients with Diffuse Large B-Cell Lymphoma Responding to First-Line R-CHOP Therapy CELG Occurred On: Jul 25, 2016
- Celgene's Phase 3 REMARC Data for non-Hodgkin Lymphoma Expected Mid-Year CELG Occurred On: Jul 25, 2016
- Phase 3 REMARC Trial Data with REVLIMID in DLBCL Maintenance Due Q4 2016 CELG Occurred On: Jul 25, 2016
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
